{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:51:24Z","timestamp":1794329484183,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,6]]},"DOI":"10.7759\/cureus.44780","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T16:32:24Z","timestamp":1694017944000},"source":"Crossref","is-referenced-by-count":3,"title":["The Effectiveness of Common Interventions in the Management of Sickle Cell Disease in Primary Care Settings: A Review"],"prefix":"10.7759","author":[{"given":"Rheiner  N","family":"Mbaezue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetoro  T","family":"Okafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard I","family":"Nkwocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidalu N","family":"Ibeneme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amoge C","family":"Opara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlington E","family":"Akahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okelue E","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Data &amp; Statistics on Sickle Cell Disease. (2022). Accessed. Accessed July 2, 2023: https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3402\/meo.v21.33616","article-title":"Translating sickle cell guidelines into practice for primary care providers with Project ECHO","volume":"21","author":"Shook LM","year":"2016","unstructured":"Shook LM, Farrell CB, Kalinyak KA, et al.. Translating sickle cell guidelines into practice for primary care providers with Project ECHO. Med Educ Online. 2016, 21:33616. 10.3402\/meo.v21.33616","journal-title":"Med Educ Online"},{"key":"ref3","article-title":"Biochemistry, hemoglobin synthesis","author":"Farid Y","year":"2023","unstructured":"Farid Y, Bowman NS, Lecat P. Biochemistry, hemoglobin synthesis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref4","article-title":"Oxygen saturation","author":"Hafen BB","year":"2023","unstructured":"Hafen BB, Sharma S. Oxygen saturation. StatPearls [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/30247849\/ (ed): StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1148\/rg.210154","article-title":"Manifestations of sickle cell disorder at abdominal and pelvic imaging","volume":"42","author":"Solomon N","year":"2022","unstructured":"Solomon N, Segaran N, Badawy M, et al.. Manifestations of sickle cell disorder at abdominal and pelvic imaging. Radiographics. 2022, 42:1103-22. 10.1148\/rg.210154","journal-title":"Radiographics"},{"key":"ref6","unstructured":"What is Sickle Cell Disease?. (2023). Accessed. July 23, 2023: https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/facts.html."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1559827609335350","article-title":"The epidemiologic transition: changing patterns of mortality and population dynamics","volume":"3","author":"McKeown RE","year":"2009","unstructured":"McKeown RE. The epidemiologic transition: changing patterns of mortality and population dynamics. Am J Lifestyle Med. 2009, 3:19S-26S. 10.1177\/1559827609335350","journal-title":"Am J Lifestyle Med"},{"key":"ref8","article-title":"Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 | NHLBI, NIH. Accessed July 2, 2023","year":"2014","unstructured":"Evidence-Based Management of Sickle Cell Disease. Expert Panel Report, 2014. National Heart, Lung, and Blood Institute, Bethesda, Maryland; 2014. https:\/\/www.nhlbi.nih.gov\/sites\/default\/files\/media\/docs\/sickle-cell-disease-report%20020816_0.pdf."},{"key":"ref9","article-title":"Transfusion in sickle cell disease: Management of complications including iron overload","author":"DeBaun MR","year":"2022","unstructured":"DeBaun MR, Chou ST. Transfusion in sickle cell disease: Management of complications including iron overload. UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2022."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in sickle cell disease: drug review","volume":"30","author":"Agrawal RK","year":"2014","unstructured":"Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014, 30:91-6. 10.1007\/s12288-013-0261-4","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/JHQ.0000000000000292","article-title":"Clinical pathway for vaso-occlusive pain reduces hospital admissions","volume":"44","author":"Jones W","year":"2022","unstructured":"Jones W, Jang A, Myers L, Dasgupta A, DeBord J. Clinical pathway for vaso-occlusive pain reduces hospital admissions. J Healthc Qual. 2022, 44:50-8. 10.1097\/JHQ.0000000000000292","journal-title":"J Healthc Qual"},{"key":"ref12","unstructured":"Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2019-2020. (2022). Accessed. 2023: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2019-2020....."},{"key":"ref13","unstructured":"Pneumococcal Vaccination. What Everyone Should Know. (2023). Accessed: 2023: https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/public\/index.html."},{"key":"ref14","unstructured":"Invasive Pneumococcal Disease among Children with and without Sickle Cell Disease in the United States, 1998-2009. (2023). Accessed. 2023: https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/features\/keyfinding-pneumococcal.html."},{"key":"ref15","article-title":"Penicillin prophylaxis in children with sickle cell disease","volume":"15","author":"Cober MP","year":"2010","unstructured":"Cober MP, Phelps SJ. Penicillin prophylaxis in children with sickle cell disease. J Pediatr Pharmacol Ther. 2010, 15:152-9.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref16","article-title":"Transfusion iron overload","author":"Rasel M","year":"2023","unstructured":"Rasel M, Mahboobi SK. Transfusion iron overload. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0221-y","article-title":"An overview of clinical decision support systems: benefits, risks, and strategies for success","volume":"3","author":"Sutton RT","year":"2020","unstructured":"Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020, 3:17. 10.1038\/s41746-020-0221-y","journal-title":"NPJ Digit Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22433.1","article-title":"Drug therapies for the management of sickle cell disease","volume":"9","author":"Rai P","year":"2020","unstructured":"Rai P, Ataga KI. Drug therapies for the management of sickle cell disease. F1000Res. 2020, 9:592. 10.12688\/f1000research.22433.1","journal-title":"F1000Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2020.010","article-title":"The evolving pharmacotherapeutic landscape for the treatment of sickle cell disease","volume":"12","author":"Ballas SK","year":"2020","unstructured":"Ballas SK. The evolving pharmacotherapeutic landscape for the treatment of sickle cell disease. Mediterr J Hematol Infect Dis. 2020, 12:e2020010. 10.4084\/MJHID.2020.010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202.pub3","article-title":"Hydroxyurea (hydroxycarbamide) for sickle cell disease","volume":"9","author":"Rankine-Mullings AE","year":"2022","unstructured":"Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2022, 9:CD002202. 10.1002\/14651858.CD002202.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/fmz070","article-title":"Effectiveness and safety of hydroxyurea in the treatment of sickle cell anaemia children in Jos, north-central Nigeria","volume":"66","author":"Ofakunrin AO","year":"2020","unstructured":"Ofakunrin AO, Oguche S, Adekola K, et al.. Effectiveness and safety of hydroxyurea in the treatment of sickle cell anaemia children in Jos, north-central Nigeria. J Trop Pediatr. 2020, 66:290-8. 10.1093\/tropej\/fmz070","journal-title":"J Trop Pediatr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000327","article-title":"Factors associated with pneumococcal nasopharyngeal carriage: a systematic review","volume":"2","author":"Neal EF","year":"2022","unstructured":"Neal EF, Chan J, Nguyen CD, Russell FM. Factors associated with pneumococcal nasopharyngeal carriage: a systematic review. PLOS Glob Public Health. 2022, 2:e0000327. 10.1371\/journal.pgph.0000327","journal-title":"PLOS Glob Public Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-051892","article-title":"Bloodstream infections in children with sickle cell disease: 2010-2019","volume":"149","author":"Yee ME","year":"2022","unstructured":"Yee ME, Lai KW, Bakshi N, et al.. Bloodstream infections in children with sickle cell disease: 2010-2019. Pediatrics. 2022, 149:10.1542\/peds.2021-051892","journal-title":"Pediatrics"},{"key":"ref24","unstructured":"Pneumococcal Disease. (2022). Accessed. July 2, 2023: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/pneumo.html."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-21.1.27","article-title":"A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens","volume":"21","author":"Daniels CC","year":"2016","unstructured":"Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016, 21:27-35. 10.5863\/1551-6776-21.1.27","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00331-7","article-title":"Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination","volume":"143","author":"Adamkiewicz TV","year":"2003","unstructured":"Adamkiewicz TV, Sarnaik S, Buchanan GR, et al.. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003, 143:438-44. 10.1067\/S0022-3476(03)00331-7","journal-title":"J Pediatr"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life","volume":"121","author":"Adamkiewicz TV","year":"2008","unstructured":"Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008, 121:562-9. 10.1542\/peds.2007-0018","journal-title":"Pediatrics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030209","article-title":"Multi-valent protein hybrid pneumococcal vaccines: a strategy for the next generation of vaccines","volume":"9","author":"Scott NR","year":"2021","unstructured":"Scott NR, Mann B, Tuomanen EI, Orihuela CJ. Multi-valent protein hybrid pneumococcal vaccines: a strategy for the next generation of vaccines. Vaccines (Basel). 2021, 9:209. 10.3390\/vaccines9030209","journal-title":"Vaccines (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.024","article-title":"Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States","volume":"40","author":"Huang L","year":"2022","unstructured":"Huang L, Wasserman M, Grant L, et al.. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine. 2022, 40:4700-8. 10.1016\/j.vaccine.2022.06.024","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002187","article-title":"Maintenance of an immunogenic response to pneumococcal vaccination in children with sickle cell disease","volume":"44","author":"Rahim MQ","year":"2022","unstructured":"Rahim MQ, Arends AM, Jacob SA. Maintenance of an immunogenic response to pneumococcal vaccination in children with sickle cell disease. J Pediatr Hematol Oncol. 2022, 44:e51-5. 10.1097\/MPH.0000000000002187","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126056","article-title":"Standard definitions of pneumococcal immunity may not accurately predict protection in adults with sickle cell disease","volume":"134","author":"Robinson TM","year":"2019","unstructured":"Robinson TM, Lanzkron SM. Standard definitions of pneumococcal immunity may not accurately predict protection in adults with sickle cell disease. Blood. 2019, 134:1014. 10.1182\/blood-2019-126056","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/03630269.2021.1954943","article-title":"Utilization of pneumococcal vaccine and penicillin prophylaxis in sickle cell disease in three African countries: assessment among healthcare providers in SickleInAfrica","volume":"45","author":"Brown BJ","year":"2021","unstructured":"Brown BJ, Madu A, Sangeda RZ, et al.. Utilization of pneumococcal vaccine and penicillin prophylaxis in sickle cell disease in three African countries: assessment among healthcare providers in SickleInAfrica. Hemoglobin. 2021, 45:163-70. 10.1080\/03630269.2021.1954943","journal-title":"Hemoglobin"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003427.pub4","article-title":"Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease","volume":"10","author":"Rankine-Mullings AE","year":"2017","unstructured":"Rankine-Mullings AE, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2017, 10:CD003427. 10.1002\/14651858.CD003427.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref34","article-title":"Iron overload and chelation","author":"Porter J","year":"2014","unstructured":"Porter J, Viprakasit V, Kattamis A. Iron overload and chelation. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT), 3rd edition. Cappellini MD, Cohen A, Porter J, et al. (ed): Thalassaemia International Federation, Nicosia (CY); 2014."},{"key":"ref35","unstructured":"Clinical Decision Support. (2019). Accessed. July 2, 2023: https:\/\/www.ahrq.gov\/cpi\/about\/otherwebsites\/clinical-decision-support\/index.html."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2450\/2022.0309-21","article-title":"Influence of user-centered clinical decision support on pediatric blood product ordering errors","volume":"21","author":"Orenstein EW","year":"2023","unstructured":"Orenstein EW, Rollins M, Jones J, Kandaswamy S, Boudreaux J, Carter AB, Josephson CD. Influence of user-centered clinical decision support on pediatric blood product ordering errors. Blood Transfus. 2023, 21:3-12. 10.2450\/2022.0309-21","journal-title":"Blood Transfus"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jen.2021.05.007","article-title":"System level informatics to improve triage practices for sickle cell disease vaso-occlusive crisis: a cluster randomized controlled trial","volume":"47","author":"Linton E","year":"2021","unstructured":"Linton E, Souffront K, Gordon L, Loo GT, Genes N, Glassberg J. System level informatics to improve triage practices for sickle cell disease vaso-occlusive crisis: a cluster randomized controlled trial. J Emerg Nurs. 2021, 47:742-51.e1. 10.1016\/j.jen.2021.05.007","journal-title":"J Emerg Nurs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187833","article-title":"Respiratory resistance and reactance in adults with sickle cell anemia: correlation with functional exercise capacity and diagnostic use","volume":"12","author":"Marinho CL","year":"2017","unstructured":"Marinho CL, Maioli MC, do Amaral JL, Lopes AJ, Melo PL. Respiratory resistance and reactance in adults with sickle cell anemia: correlation with functional exercise capacity and diagnostic use. PLoS One. 2017, 12:e0187833. 10.1371\/journal.pone.0187833","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3479","article-title":"Pharmacogenetics for safe codeine use in sickle cell disease","volume":"138","author":"Gammal RS","year":"2016","unstructured":"Gammal RS, Crews KR, Haidar CE, et al.. Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics. 2016, 138:20153479. 10.1542\/peds.2015-3479","journal-title":"Pediatrics"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2021.21535","article-title":"Dissemination of evidence-based recommendations for sickle cell disease to primary care and emergency department providers in North Carolina: a cost benefit analysis","volume":"8","author":"Tanabe P","year":"2021","unstructured":"Tanabe P, Blewer AL, Bonnabeau E, et al.. Dissemination of evidence-based recommendations for sickle cell disease to primary care and emergency department providers in North Carolina: a cost benefit analysis. J Health Econ Outcomes Res. 2021, 8:18-28. 10.36469\/jheor.2021.21535","journal-title":"J Health Econ Outcomes Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011175.pub2","article-title":"Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications","volume":"10","author":"Asnani MR","year":"2016","unstructured":"Asnani MR, Quimby KR, Bennett NR, Francis DK. Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications. Cochrane Database Syst Rev. 2016, 10:CD011175. 10.1002\/14651858.CD011175.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15846","article-title":"Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature","volume":"185","author":"Oligbu G","year":"2019","unstructured":"Oligbu G, Fallaha M, Pay L, Ladhani S. Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. Br J Haematol. 2019, 185:743-51. 10.1111\/bjh.15846","journal-title":"Br J Haematol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1065377","article-title":"Clinical genome editing to treat sickle cell disease-a brief update","volume":"9","author":"Zarghamian P","year":"2022","unstructured":"Zarghamian P, Klermund J, Cathomen T. Clinical genome editing to treat sickle cell disease-a brief update. Front Med (Lausanne). 2022, 9:1065377. 10.3389\/fmed.2022.1065377","journal-title":"Front Med (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/173804-the-effectiveness-of-common-interventions-in-the-management-of-sickle-cell-disease-in-primary-care-settings-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:04Z","timestamp":1707509104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/173804-the-effectiveness-of-common-interventions-in-the-management-of-sickle-cell-disease-in-primary-care-settings-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.44780","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}